Published in Curr Cardiovasc Imaging Rep on November 29, 2011
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
Targeting and therapeutic peptides in nanomedicine for atherosclerosis. Exp Biol Med (Maywood) (2016) 0.79
Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater (2015) 0.78
The melding of nanomedicine in thrombosis imaging and treatment: a review. Future Sci OA (2016) 0.75
Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding. Curr Cardiol Rev (2016) 0.75
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation (2003) 3.58
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation (2001) 2.55
Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation (2005) 2.45
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol (2005) 1.88
p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol (2007) 1.80
Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation (2002) 1.77
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol (2009) 1.76
Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A (2009) 1.76
Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol (2009) 1.71
Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol (2009) 1.64
The vascular biology of atherosclerosis and imaging targets. J Nucl Med (2010) 1.45
Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol (2006) 1.33
Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol (2010) 1.32
Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol (2011) 1.32
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomater (2008) 1.11
Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett (2010) 1.08
A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small (2010) 1.07
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost (2011) 1.06
Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med (2008) 1.01
Peripheral artery disease. Part 2: medical and endovascular treatment. Nat Rev Cardiol (2011) 0.94
Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med (2010) 0.90
Standardization of models and methods used to assess nanoparticles in cardiovascular applications. Small (2011) 0.88
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol (2006) 3.36
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol (2011) 3.21
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med (2006) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Optimization of ex vivo CT- and MR- imaging of atherosclerotic vessel wall changes. Int J Cardiovasc Imaging (2004) 2.04
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Cytoarchitecture of the human cerebral cortex: MR microscopy of excised specimens at 9.4 Tesla. AJNR Am J Neuroradiol (2002) 1.98
MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med (2012) 1.92
Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology (2009) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging (2012) 1.85
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol (2002) 1.79
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov (2004) 1.71
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol (2005) 1.67
Mouse model of heterotopic aortic arch transplantation. J Surg Res (2003) 1.66
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett (2008) 1.62
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Use of a disposable acupressure device as part of a multimodal antiemetic strategy for reducing postoperative nausea and vomiting. Anesth Analg (2012) 1.57
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med (2010) 1.57
Risk scores predict atherosclerotic lesions in young people. Arch Intern Med (2005) 1.56
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Assessment of myocardial perfusion and viability from routine contrast-enhanced 16-detector-row computed tomography of the heart: preliminary results. Eur Radiol (2005) 1.55
Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging (2007) 1.52
In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging (2008) 1.52
Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol (2005) 1.50
Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. JACC Cardiovasc Imaging (2012) 1.48
Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm (2013) 1.48
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46
Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. Sci Signal (2012) 1.45
Perioperative rofecoxib improves early recovery after outpatient herniorrhaphy. Anesth Analg (2004) 1.45
Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett (2006) 1.42
The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification. Anesth Analg (2003) 1.42
Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. Cancer Biol Ther (2010) 1.42
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol (2008) 1.41
Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis (2009) 1.40
Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.38
Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem (2008) 1.37
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest (2006) 1.35
An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small (2008) 1.34
Does shear stress modulate both plaque progression and regression in the thoracic aorta? Human study using serial magnetic resonance imaging. J Am Coll Cardiol (2005) 1.33
In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol (2002) 1.33
Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med (2009) 1.31
Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation (2005) 1.31
IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res (2011) 1.30
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg (2009) 1.29
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol (2004) 1.27
Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett (2005) 1.27
Rapid extended coverage simultaneous multisection black-blood vessel wall MR imaging. Radiology (2004) 1.26
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med (2007) 1.25
Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging (2008) 1.25
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. Circulation (2011) 1.23